SynthesisPloS one2025
Efficacy of prophylactic tranexamic acid among parturient at increased risk for postpartum hemorrhage undergoing cesarean delivery: A systematic review and meta-analyses of randomized controlled trials.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostpartum hemorrhage (PPH) remains a significant cause of maternal morbidity and mortality worldwide. Prophylactic pharmacological interventions, especially tranexamic acid (TXA), are under evaluation for their efficacy in preventing PPH during cesarean sections in high-risk women. This systematic review and meta-analysis aimed to assess the effectiveness of prophylactic tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
methodsThis systematic review and meta-analysis followed the PRISMA 2020 guidelines and was registered in the PROSPERO database (ID: CRD42024520613). We conducted a comprehensive search in several bibliographic databases for randomized controlled trials comparing prophylactic tranexamic acid to placebo in parturients at increased risk for PPH undergoing cesarean delivery published until 1st, 2024. We sought trials in the United States National Library of Medicine, Cochrane Database of Systematic Reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, National Institutes of Health PubMed/MEDLINE, Web of Science, and Google Scholar databases. Primary outcomes included intraoperative blood loss, while secondary outcomes covered hemoglobin loss, transfusion needs, the incidence of PPH, and side effects.
resultsEleven randomized controlled trials involving 1627 patients were included. The meta-analysis revealed that TXA significantly reduces intraoperative blood loss compared to placebo (Mean Difference (MD) = -343.89, 95% CI [-394.34, -293.43], p < 0.00001). Furthermore, TXA was associated with lower rates of blood transfusions and PPH. The heterogeneity was substantial across studies but reduced significantly in subgroup analyses. No significant differences in side effects, hysterectomy, or additional uterotonic use were observed between the two groups.
conclusionsProphylactic tranexamic acid significantly reduces intraoperative blood loss and the incidence of PPH in parturients at increased risk undergoing cesarean delivery, without increasing side effects. These findings support the broader use of TXA in this high-risk group, although further research is necessary to explore long-term outcomes and optimal administration protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.